Ductal adenocarcinoma (DAC) is the most common variant histological subtype of prostate carcinoma and has an aggressive clinical course. DAC is usually characterized and treated as high-risk prostatic acinar adenocarcinoma (PAC). However, DAC has a different biology to that of acinar disease, which often poses a challenge for both diagnosis and management. DAC can be difficult to identify using conventional diagnostic modalities such as serum PSA levels and multiparametric MRI, and the optimal management for localized DAC is unknown owing to the rarity of the disease. Following definitive therapy for localized disease with radical prostatectomy or radiotherapy, the majority of DACs recur with visceral metastases at low PSA levels. Various systemic therapies that have been shown to be effective in high-risk PAC have limited use in treating DAC. Although current understanding of the biology of DAC is limited, genomic analyses have provided insights into the pathology behind its aggressive behaviour and potential future therapeutic targets.
Ductal adenocarcinoma (DAC) is the most common variant histological subtype of prostate carcinoma, which has a unique and aggressive biology.
In contrast to prostatic acinar adenocarcinoma (PAC), the majority of DACs present with lower urinary tract symptoms, have a low serum PSA and are often clinically under-staged.
DAC tends to present with advanced disease and has poor outcomes with surgery or radiotherapy compared with high-risk PAC. Multimodal therapies are often needed upfront when treating localized DAC.
The genomic makeup of DAC resembles castration-resistant PAC and warrants aggressive therapy, including the use of upfront use of novel systemic or combination therapies in neoadjuvant, adjuvant and metastatic settings.
Aggressive surveillance post-radical therapy for localized disease with imaging, including CT of the chest, is warranted, as patients with DAC develop bony and visceral metastases at low PSA levels.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Knipper, S. et al. Contemporary comparison of clinicopathologic characteristics and survival outcomes of prostate ductal carcinoma and acinar adenocarcinoma: a population-based study. Clin. Genitourin. Cancer 17, 231–237.e2 (2019).
Samaratunga, H., Duffy, D., Yaxley, J. & Delahunt, B. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Hum. Pathol. 41, 281–285 (2010).
Vinceneux, A. et al. Ductal adenocarcinoma of the prostate: clinical and biological profiles. Prostate 77, 1242–1250 (2017).
Jang, W. S. et al. Prognostic significance of the proportion of ductal component in ductal adenocarcinoma of the prostate. J. Urol. 197, 1048–1053 (2017).
Harkin, T. et al. High ductal proportion predicts biochemical recurrence in prostatic ductal adenocarcinoma. BJU Int. 124, 907–909 (2019).
Jeong, S. U. et al. Diverse immunoprofile of ductal adenocarcinoma of the prostate with an emphasis on the prognostic factors. J. Pathol. Transl Med. 51, 471–481 (2017).
Christensen, W. N., Steinberg, G., Walsh, P. C. & Epstein, J. I. Prostatic duct adenocarcinoma. Findings at radical prostatectomy. Cancer 67, 2118–2124 (1991).
Seipel, A. H., Wiklund, F., Wiklund, N. P. & Egevad, L. Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens. Virchows Arch. 462, 429–436 (2013).
Kim, A. et al. Clinicopathological features of prostate ductal carcinoma: matching analysis and comparison with prostate acinar carcinoma. J. Korean Med. Sci. 30, 385–389 (2015).
Tu, S. M. et al. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer 115, 2872–2880 (2009).
Morgan, T. M., Welty, C. J., Vakar-Lopez, F., Lin, D. W. & Wright, J. L. Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J. Urol. 184, 2303–2307 (2010).
Gillard, M. et al. Integrative genomic analysis of coincident cancer foci implicates CTNNB1 and PTEN alterations in ductal prostate cancer. Eur. Urol. Focus 5, 433–442 (2019).
Millar, E. K., Sharma, N. K. & Lessells, A. M. Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathological study of 16 cases. Histopathology 29, 11–19 (1996).
Orihuela, E. & Green, J. M. Ductal prostate cancer: contemporary management and outcomes. Urol. Oncol. 26, 368–371 (2008).
Epstein, J. I. Prostatic ductal adenocarcinoma: a mini review. Med. Princ. Pract. 19, 82–85 (2010).
Bock, B. J. & Bostwick, D. G. Does prostatic ductal adenocarcinoma exist? Am. J. Surg. Pathol. 23, 781–785 (1999).
Melicow, M. M. & Pachter, M. R. Endometrial carcinoma of proxtatic utricle (uterus masculinus). Cancer 20, 1715–1722 (1967).
Seipel, A. H. et al. Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. Histopathology 65, 216–227 (2014).
Au, S., Villamil, C. F., Alaghehbandan, R. & Wang, G. Prostatic ductal adenocarcinoma with cribriform architecture has worse prognostic features than non-cribriform-type. Ann. Diagn. Pathol. 39, 59–62 (2019).
Samaratunga, H. & Letizia, B. Prostatic ductal adenocarcinoma presenting as a urethral polyp: a clinicopathological study of eight cases of a lesion with the potential to be misdiagnosed as a benign prostatic urethral polyp. Pathology 39, 476–481 (2007).
Zhou, M. High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate. Mod. Pathol. 31, S71–S79 (2018).
Tavora, F. & Epstein, J. I. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases. Am. J. Surg. Pathol. 32, 1060–1067 (2008).
Epstein, J. I. et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am. J. Surg. Pathol. 40, 244–252 (2016).
Srigley, J. R. et al. Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. Pathology 51, 463–473 (2019).
Amin, A. & Epstein, J. I. Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: effect of percentage of the ductal component and associated grade of acinar adenocarcinoma. Am. J. Surg. Pathol. 35, 615–619 (2011).
Seipel, A. H. et al. Immunohistochemical profile of ductal adenocarcinoma of the prostate. Virchows Arch. 465, 559–565 (2014).
Sha, J. et al. Ductal adenocarcinoma of the prostate: immunohistochemical findings and clinical significance. Onco Targets Ther. 6, 1501–1506 (2013).
Tarjan, M., Lenngren, A., Hellberg, D. & Tot, T. Immunohistochemical verification of ductal differentiation in prostate cancer. APMIS 120, 510–518 (2012).
Leite, K. R. et al. Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer. Ann. Diagn. Pathol. 12, 260–266 (2008).
Morais, C. L. et al. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas. Prostate 75, 1610–1619 (2015).
Lindh, C. et al. PD-L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate. APMIS 127, 554–560 (2019).
Park, C. K., Shin, S. J., Cho, Y. A., Joo, J. W. & Cho, N. H. HoxB13 expression in ductal type adenocarcinoma of prostate: clinicopathologic characteristics and its utility as potential diagnostic marker. Sci. Rep. 9, 20205 (2019).
Varma, M., Delahunt, B., Egevad, L., Samaratunga, H. & Kristiansen, G. Intraductal carcinoma of the prostate: a critical re-appraisal. Virchows Arch. 474, 525–534 (2019).
Meeks, J. J., Zhao, L. C., Cashy, J. & Kundu, S. Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the Surveillance, Epidemiology, and End Results program. BJU Int. 109, 831–834 (2012).
Dube, V. E., Farrow, G. M. & Greene, L. F. Prostatic adenocarcinoma of ductal origin. Cancer 32, 402–409 (1973).
Brinker, D. A., Potter, S. R. & Epstein, J. I. Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am. J. Surg. Pathol. 23, 1471–1479 (1999).
McNeal, J. E. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum. Pathol. 23, 258–266 (1992).
Haffner, J. et al. Peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology. Prostate 69, 276–282 (2009).
Shannon, B. A., McNeal, J. E. & Cohen, R. J. Transition zone carcinoma of the prostate gland: a common indolent tumour type that occasionally manifests aggressive behaviour. Pathology 35, 467–471 (2003).
Iakymenko, O. A. et al. Prostatic ductal adenocarcinoma controlled for cancer grade and tumor volume does not have an independent effect on adverse radical prostatectomy outcomes compared to usual acinar prostatic adenocarcinoma. Urology 137, 108–114 (2020).
Tarjan, M. et al. Improved differentiation between ductal and acinar prostate cancer using three-dimensional histology and biomarkers. Scand. J. Urol. Nephrol. 46, 258–266 (2012).
Gong, Y., Caraway, N., Stewart, J. & Staerkel, G. Metastatic ductal adenocarcinoma of the prostate: cytologic features and clinical findings. Am. J. Clin. Pathol. 126, 302–309 (2006).
Seipel, A. H., Delahunt, B., Samaratunga, H. & Egevad, L. Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features. Pathology 48, 398–405 (2016).
Ranasinghe, W. K. B. et al. Patterns of metastases of prostatic ductal adenocarcinoma. Cancer 126, 3667–3673 (2020).
Tu, S. M. et al. Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer 94, 2610–2617 (2002).
Ellis, C. L. & Epstein, J. I. Metastatic prostate adenocarcinoma to the penis: a series of 29 cases with predilection for ductal adenocarcinoma. Am. J. Surg. Pathol. 39, 67–74 (2015).
Collina, G., Reggiani, C. & Carboni, G. Ductal carcinoma of the prostate metastatic to the skin. Pathologica 103, 50–51 (2011).
Gzell, C. E., Kench, J. G., Stockler, M. R. & Hruby, G. Biopsy-proven brain metastases from prostate cancer: a series of four cases with review of the literature. Int. Urol. Nephrol. 45, 735–742 (2013).
Wu, T. et al. Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer? Prostate 79, 1673–1682 (2019).
Ranasinghe, W. et al. Ductal prostate cancers demonstrate poor outcomes with conventional therapies. Eur. Urol. 79, 298–306 (2021).
Lilja, H., Ulmert, D. & Vickers, A. J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 8, 268–278 (2008).
Bostwick, D. G., Kindrachuk, R. W. & Rouse, R. V. Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am. J. Surg. Pathol. 9, 595–609 (1985).
Packiam, V. T. et al. Contemporary population-based comparison of localized ductal adenocarcinoma and high-risk acinar adenocarcinoma of the prostate. Urology 86, 777–782 (2015).
Bergamin, S. et al. Ductal carcinoma of the prostate: an uncommon entity with atypical behaviour. Clin. Oncol. 31, 108–114 (2019).
Leibovici, D. et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 109, 198–204 (2007).
Bilen, M. A. et al. Variant prostate carcinoma and elevated serum CA-125. Can. J. Urol. 21, 7442–7448 (2014).
Ji, C. et al. Advanced prostatic ductal carcinoma in a patient with a long survival time following a total pelvis exenteration: a case report. Oncol. Lett. 11, 1509–1511 (2016).
Kabawat, S. E. et al. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int. J. Gynecol. Pathol. 2, 275–285 (1983).
Hall, C. et al. A review of the role of carcinoembryonic antigen in clinical practice. Ann. Coloproctol. 35, 294–305 (2019).
Liu, T. et al. The update of prostatic ductal adenocarcinoma. Chin. J. Cancer Res. 28, 50–57 (2016).
Coffey, N. et al. Multi-parametric (mp) MRI of prostatic ductal adenocarcinoma. J. Magn. Reson. Imaging 41, 1639–1645 (2015).
Schieda, N. et al. Prostatic ductal adenocarcinoma: an aggressive tumour variant unrecognized on T2 weighted magnetic resonance imaging (MRI). Eur. Radiol. 24, 1349–1356 (2014).
Ranasinghe, W. K. B. et al. Defining diagnostic criteria for ductal prostate cancer on prostatic MRI [Abstract e17532]. J. Clin. Oncol. 38, e17532–e17532 (2020).
Henderson-Jackson, E. et al. Cystic prostatic ductal adenocarcinoma: an unusual presentation and cytological diagnosis. Ann. Clin. Lab. Sci. 42, 81–88 (2012).
Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395, 1208–1216 (2020).
Perera, M. et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur. Urol. 77, 403–417 (2020).
Hruby, G. et al. Delineating biochemical failure with (68)Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. Radiother. Oncol. 122, 99–102 (2017).
McEwan, L. M., Wong, D. & Yaxley, J. Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative. J. Med. Imaging Radiat. Oncol. 61, 503–505 (2017).
Wallitt, K. L. et al. Clinical PET imaging in prostate cancer. Radiographics 37, 1512–1536 (2017).
Beauregard, J. M. et al. FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. Cancer Imaging 15, 2 (2015).
Jadvar, H. et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin. Nucl. Med. 37, 637–643 (2012).
Petrelli, F. et al. Radical prostatectomy or radiotherapy in high-risk prostate cancer: a systematic review and metaanalysis. Clin. Genitourin. Cancer 12, 215–224 (2014).
Soeterik, T. F. W. et al. Nerve sparing during robot-assisted radical prostatectomy increases the risk of ipsilateral positive surgical margins. J. Urol. 204, 91–95 (2020).
Fossati, N. et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur. Urol. 72, 84–109 (2017).
Eade, T. N. et al. Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. Cancer 109, 2011–2015 (2007).
Sanda, M. G. et al. Clinically localized prostate cancer: AUA/ASTRA/SUO Guideline. Part I: Risk stratification, shared decision making, and care options. J. Urol. 199, 683–690 (2018).
Zhi, M. & Soper, M. S. Ductal adenocarcinoma of the prostate gland treated with radical prostatectomy or radiation therapy: a single institutional retrospective review with long-term follow-up. Int. J. Radiat. Oncol. 99, E280–E281 (2017).
Igdem, S. et al. Prostatic duct adenocarcinoma: clinical characteristics, treatment options, and outcomes — a Rare Cancer Network study. Onkologie 33, 169–173 (2010).
Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48, 202–205; discussion 205–206 (2005).
McKay, R. R. et al. Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone. J. Clin. Oncol. 37, 923–931 (2019).
Nakamura, K. et al. Clinical characteristics of prostate ductal adenocarcinoma in kyoto university hospital. Hinyokika Kiyo 61, 487–491 (2015).
Wang, X. et al. Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers. Prostate 79, 709–719 (2019).
Shannon, C. & Smith, I. Is there still a role for neoadjuvant therapy in breast cancer? Crit. Rev. Oncol. Hematol. 45, 77–90 (2003).
Maithel, S. K. & D’Angelica, M. I. An update on randomized clinical trials in advanced and metastatic colorectal carcinoma. Surg. Oncol. Clin. N. Am. 19, 163–181 (2010).
Koupparis, A. & Gleave, M. E. Multimodal approaches to high-risk prostate cancer. Curr. Oncol. 17 (Suppl 2), 33–37 (2010).
Tosco, L. et al. Systematic review of systemic therapies and therapeutic combinations with local treatments for high-risk localized prostate cancer. Eur. Urol. 75, 44–60 (2019).
Morris, W. J. et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 98, 275–285 (2017).
Fizazi, K. et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol. 16, 787–794 (2015).
Rosenthal, S. A. et al. Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG oncology RTOG 0521 trial. J. Clin. Oncol. 37, 1159–1168 (2019).
Aydin, H. et al. Ductal adenocarcinoma of the prostate diagnosed on transurethral biopsy or resection is not always indicative of aggressive disease: implications for clinical management. BJU Int. 105, 476–480 (2010).
Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737–746 (2015).
James, N. D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387, 1163–1177 (2016).
Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377, 352–360 (2017).
James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338–351 (2017).
Kan, R. W. et al. Ductal adenocarcinoma of the prostate: a Hong Kong case series. Int. Urol. Nephrol. 46, 2133–2137 (2014).
Kumar, A. & Mukherjee, S. D. Metastatic ductal carcinoma of the prostate: a rare variant responding to a common treatment. Can. Urol. Assoc. J. 4, E50–E54 (2010).
Fujiwara, R. et al. Metastatic prostatic ductal adenocarcinoma successfully treated with docetaxel chemotherapy: a case report. Case Rep. Oncol. 8, 339–344 (2015).
Paterson, C., Correa, P. D. & Russell, J. M. Ductal variant of adenocarcinoma prostate responding to docetaxel — a case report. Clin. Oncol. 22, 617 (2010).
Linden-Castro, E. et al. Abiraterone acetate and castration resistant ductal adenocarcinoma of the prostate. Case Rep. Urol. 2014, 508305 (2014).
Martorana, E. et al. Management and therapeutic response of a prostate ductal adenocarcinoma: a still unknown tumour? Urologia 83, 163–167 (2016).
Kato, T. et al. Carbohydrate antigen 19-9-positive prostatic ductal adenocarcinoma effectively treated with cisplatin and gemcitabine. Int. J. Urol. 14, 1103–1106 (2007).
Connor, M. J. et al. Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nat. Rev. Clin. Oncol. 17, 168–182 (2020).
Seipel, A. H. et al. Genetic profile of ductal adenocarcinoma of the prostate. Hum. Pathol. 69, 1–7 (2017).
Schweizer, M. T. et al. Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations. JCO Precis. Oncol. 3, PO.18.00327 (2019).
Sanati, S., Watson, M. A., Salavaggione, A. L. & Humphrey, P. A. Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate. Mod. Pathol. 22, 1273–1279 (2009).
Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011–1025 (2015).
Armenia, J. et al. The long tail of oncogenic drivers in prostate cancer. Nat. Genet. 50, 645–651 (2018).
Kypta, R. M. & Waxman, J. Wnt/beta-catenin signalling in prostate cancer. Nat. Rev. Urol. 9, 418–428 (2012).
Murillo-Garzon, V. & Kypta, R. WNT signalling in prostate cancer. Nat. Rev. Urol. 14, 683–696 (2017).
Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239–243 (2012).
Park, S., Kim, Y. S., Kim, D. Y., So, I. & Jeon, J. H. PI3K pathway in prostate cancer: all resistant roads lead to PI3K. Biochim. Biophys. Acta Rev. Cancer 1870, 198–206 (2018).
Jamaspishvili, T. et al. Clinical implications of PTEN loss in prostate cancer. Nat. Rev. Urol. 15, 222–234 (2018).
Lotan, T. L. et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Mod. Pathol. 22, 359–365 (2009).
Han, B. et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod. Pathol. 22, 1176–1185 (2009).
Guo, C. C., Zuo, G., Cao, D., Troncoso, P. & Czerniak, B. A. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod. Pathol. 22, 866–871 (2009).
Gopalan, A. et al. TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry. Histopathology 63, 279–286 (2013).
Gu, L. et al. Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: a meta-analysis. Crit. Rev. Oncol. Hematol. 147, 102888 (2020).
Virtanen, V. et al. PARP inhibitors in prostate cancer — the preclinical rationale and current clinical development. Genes 10, 565 (2019).
Heeke, A. L. et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis. Oncol. 2018, PO.17.00286 (2018).
Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443–453 (2016).
Litton, J. K. et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J. Clin. Oncol. 38, 388–394 (2020).
Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
Ozdemir, B. C., Siefker-Radtke, A. O., Campbell, M. T. & Subudhi, S. K. Current and future applications of novel immunotherapies in urological oncology: a critical review of the literature. Eur. Urol. Focus 4, 442–454 (2018).
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
Beer, T. M. et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 35, 40–47 (2017).
Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700–712 (2014).
Gao, J. et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat. Med. 23, 551–555 (2017).
Lu, X. et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543, 728–732 (2017).
Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).
Martin, A. M. et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 18, 325–332 (2015).
Drake, C. G. Visceral metastases and prostate cancer treatment: ‘die hard,’ ‘tough neighborhoods,’ or ‘evil humors’? Oncology 28, 974–980 (2014).
Brown, J. S., Sundar, R. & Lopez, J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. Br. J. Cancer 118, 312–324 (2018).
Jiao, S. et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin. Cancer Res. 23, 3711–3720 (2017).
Criscuolo, D. et al. New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder cancer treatment. J. Exp. Clin. Cancer Res. 38, 91 (2019).
Shen, J. et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCANESS. Cancer Res. 79, 311–319 (2019).
Ding, L. et al. PARP inhibition elicits sting-dependent antitumor immunity in BRCA1-deficient ovarian cancer. Cell Rep. 25, 2972–2980.e5 (2018).
Lawrence, M. G. et al. Knowing what’s growing: why ductal and intraductal prostate cancer matter. Sci. Transl Med. 12, eaaz0152 (2020).
Jiang, M. et al. cGAS-STING, an important pathway in cancer immunotherapy. J. Hematol. Oncol. 13, 81 (2020).
Epstein, J. I., Partin, A. W., Sauvageot, J. & Walsh, P. C. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am. J. Surg. Pathol. 20, 286–292 (1996).
The authors thank Patricia Troncoso, Department of Pathology, University of Texas, MD Anderson Cancer Center, for input with proofreading of the manuscript before submission, and the medical illustrator, Kelly Kage from the Division of Diagnostic Imaging, MD Anderson Cancer Center.
The authors declare no competing interests.
Peer review information
Nature Reviews Urology thanks A. Antonelli, T. Bismar, L. Egevad and D. Murphy for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Amphophilic cytoplasm
Cell cytoplasm stains with both basic and acidic dyes on histology staining.
- Endometrial tumour
A tumour that originates from the endometrial lining of the uterus. Ductal adenocarcinoma of the prostate was originally thought to histologically resemble an endometrial tumour.
- Prostate-specific membrane antigen
(PSMA). A prostate-specific transmembrane protein that is overexpressed in prostate cancers.
- Ki-67 proliferation index
A marker of cell proliferation where higher levels are associated with more aggressive tumours.
- Mullerian vestige
Non-functional remnants of embryological Mullerian ducts that give rise to the female organs (vagina, uterus and fallopian tubes) and regresses in males.
- KEGG pathway analysis
A compilation of genomic, biological, disease and chemical databases and is used in bioinformatics analyses including identification of biological pathways associated with different genes.
- Mismatch repair mutations
Mutations of genes that repair mis-paired bases after DNA replication, which results in biosynthetic errors and tumour development.
- cGAS–STING pathway
A central cellular cytosolic double-stranded DNA sensor, allowing innate immune response to infections, inflammation and cancer.
About this article
Cite this article
Ranasinghe, W., Shapiro, D.D., Zhang, M. et al. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol (2021). https://doi.org/10.1038/s41585-021-00447-3